Hepatitis B virus infection--natural history and clinical consequences.
暂无分享,去创建一个
[1] A. Prince,et al. Infectivity of blood from PCR‐positive, HBsAg‐negative, anti‐HBs‐positive cases of resolved hepatitis B infection , 2001, Transfusion.
[2] R. Beasley. Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.
[3] R. Tedder,et al. Evidence for a dynamic host‐parasite relationship in e‐negative hepatitis B carriers , 2002, Journal of medical virology.
[4] D. S. Dane,et al. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. , 1970, Lancet.
[5] G. Jay,et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice , 1991, Nature.
[6] K. Molnar-Kimber,et al. Viral nucleic acid synthesis and antigen accumulation in pancreas and kidney of Pekin ducks infected with duck hepatitis B virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[7] E. Schiff,et al. Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.
[8] Y. Liaw,et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.
[9] F. Chisari. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. , 1996, Current topics in microbiology and immunology.
[10] A. Prince,et al. IMMUNOHISTOCHEMICAL STUDIES ON THE ETIOLOGY OF ANICTERIC HEPATITIS IN KOREA. , 1964, American journal of hygiene.
[11] M. Manns,et al. In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.
[12] G. Fourel,et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours , 1990, Nature.
[13] P. Hofschneider,et al. The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene , 1992, Journal of virology.
[14] J. Wands,et al. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.
[15] A. Prince,et al. TIlE ETIOLOGY OF CHRlIONIC ACTIVE HEPATITIS IN KOREA PLATE , 2008 .
[16] A M Prince,et al. An antigen detected in the blood during the incubation period of serum hepatitis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Beasley,et al. Vertical transmission of hepatitis B antigen in Taiwan. , 1975, The New England journal of medicine.
[18] B. Gazzard,et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.
[19] F Tsuda,et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen , 1990, Journal of virology.
[20] R. Sprengel,et al. Replication strategy of human hepatitis B virus , 1987, Journal of virology.
[21] R. Purcell,et al. Hepatitis B virus infection in chimpanzees: titration of subtypes. , 1975, The Journal of infectious diseases.
[22] B. Tennant,et al. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. , 1988, Virology.
[23] Nicholson,et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir , 2000, Journal of viral hepatitis.
[24] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[25] H. Kumada,et al. [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[26] Ruy M Ribeiro,et al. Dynamics of hepatitis B virus infection. , 2002, Microbes and infection.
[27] Marion Pl. Use of animal models to study hepatitis B virus. , 1988 .
[28] F. Chisari,et al. Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.
[29] P. Tebas,et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. , 2002, The Journal of infectious diseases.
[30] Prince Am,et al. The etiology of chronic active hepatitis in Korea. , 1979 .
[31] Chien-Jen Chen,et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.
[32] T. Tokino,et al. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. , 1990, Molecular biology & medicine.
[33] G. Meucci,et al. The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers , 1993, Annals of Internal Medicine.
[34] E. Wiedenmann,et al. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). , 2000, Journal of virological methods.
[35] F. Zoulim,et al. Woodchuck hepatitis virus X protein is required for viral infection in vivo , 1994, Journal of virology.
[36] E. De Clercq,et al. 5′-Nor Carbocyclic 5′-Deoxy-5′-(Isobutylthio)Adenosine and a 2′,3′-Dideoxy-2′,3′-Didehydro Derivative , 2001, Antiviral chemistry & chemotherapy.
[37] J. Summers,et al. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Schinazi,et al. Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection , 2001, Antimicrobial Agents and Chemotherapy.
[39] T. Wright,et al. Clinical aspects of hepatitis B virus infection , 1993, The Lancet.
[40] M. Imai,et al. Immunochemical structure of hepatitis B e antigen in the serum. , 1983, Journal of immunology.
[41] R. Bruno,et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. , 2002, AIDS reviews.
[42] R. Locksley,et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. , 2002, Immunity.
[43] I. Millman,et al. Virus-like particles in Australia antigen-associated hepatitis. , 1972 .
[44] N. Leung,et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen‐negative chronic hepatitis B virus‐infected patients , 2002, Journal of viral hepatitis.
[45] B. McMahon,et al. Chronic hepatitis B , 2001, Hepatology.
[46] H. Alter,et al. A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.
[47] A. Prince,et al. ANICTERIC HEPATITIS IN KOREA. II. SERIAL HISTOLOGIC STUDIES. , 1964, Archives of internal medicine.
[48] M. Manns,et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 2001, Antimicrobial agents and chemotherapy.
[49] H. Will,et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[50] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[51] S. Krugman,et al. Viral hepatitis. New light on an old disease. , 1970, JAMA.
[52] D. Ganem,et al. The role of envelope proteins in hepatitis B virus assembly. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[53] C. Seeger,et al. Novel mechanism for reverse transcription in hepatitis B viruses , 1993, Journal of virology.
[54] F. Chisari,et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.
[55] J. Kao. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics , 2002, Journal of gastroenterology and hepatology.
[56] J. Villeneuve,et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.
[57] D. Häussinger,et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.
[58] J. Pollack,et al. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis , 1994, Journal of virology.
[59] Y. Liaw,et al. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.
[60] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[61] R. Purcell,et al. Hepatocarcinogenicity of the woodchuck hepatitis virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[62] U. Klingmüller,et al. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor , 1993, Journal of virology.
[63] J. Summers,et al. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.
[64] M. Timbury. Infectious Hepatitis: Evidence for Two Distinctive Clinical, Epidemiological, and Immunological Types of Infection , 1997, Reviews in medical virology.
[65] W. Szmuness,et al. Immunologic distinction between infectious and serum hepatitis. , 1970, The New England journal of medicine.
[66] R. Koff,et al. Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. , 1977, Gastroenterology.
[67] J. Cullen,et al. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte , 1994, Journal of virology.
[68] B. McMahon,et al. Chronic hepatitis B , 2001, Hepatology.
[69] J. Hoofnagle,et al. Serologic Markers of Hepatitis B Virus Infection , 1986, Annual review of medicine.
[70] G. Alexander,et al. Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.
[71] C. Chu,et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.
[72] H. Van Vlierberghe,et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.
[73] D. Ganem,et al. Assembly of hepadnaviral virions and subviral particles. , 1991, Current topics in microbiology and immunology.
[74] Illiam,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[75] R. Schinazi,et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. , 2001, Antiviral chemistry & chemotherapy.
[76] C. Gibbs,et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.
[77] F. Chisari,et al. Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice , 1998, Journal of Virology.
[78] A. Prince. Relation of Australia and SH antigens. , 1968, Lancet.
[79] J. Summers,et al. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.
[80] E. Schiff,et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.
[81] R. D. de Man,et al. Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.
[82] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[83] L. Guillevin,et al. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. , 2001, Journal of autoimmunity.
[84] K. Chayama,et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus , 1998, Cancer.
[85] J. Gornbein,et al. New Era of Liver Transplantation for Hepatitis B: A 17-Year Single-Center Experience , 2002, Annals of surgery.